Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
6.35M
-
Shares change
-
-328K
-
Total reported value, excl. options
-
$20.6M
-
Value change
-
-$1.16M
-
Number of buys
-
6
-
Number of sells
-
-9
-
Price
-
$3.24
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q2 2022
22 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2022.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.35M shares
of 49.6M outstanding shares and own 12.79% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1.94M shares), FRANKLIN RESOURCES INC (1.13M shares), FMR LLC (899K shares), Sands Capital Ventures, LLC (812K shares), Point72 Asset Management, L.P. (743K shares), VANGUARD GROUP INC (405K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (133K shares), BlackRock Inc. (129K shares), GEODE CAPITAL MANAGEMENT, LLC (75.2K shares), and STATE STREET CORP (27.6K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.